Floatz logo

Cynk-001

Immunoproliferative Disorder

Celularity IncorporatedCell therapyPhase 1Dormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

10 Active assets in the Immunoproliferative Disorder cohort.

Asset / SponsorPhaseRating
Zilovertamab
Oncternal Therapeutics, Inc
Phase 3B
Ibrutinib
Oncternal Therapeutics, Inc
Phase 3B
Jcar017 (Lisocabtagene Maraleucel)
Juno Therapeutics, a Subsidiary of Celgene
Phase 2B
Tucidinostat
Fudan University
Phase 2CCC
Fludarabine
UNC Lineberger Comprehensive Cancer Center
Phase 1CC

View all 12 →

Same molecule, other indications

Cynk-001 is also rated in:

giant cell glioblastomaDormant
C
Indicative ·
37 / 100
View asset →
glioblastomaDormant
C
Indicative ·
37 / 100
View asset →
monoclonal paraproteinemia diseaseDormant
D
Indicative ·
30 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →